Skip to main content
SpringerLink
Log in

Combination with Hyperthermia and Chemotherapy: Liver Cancer

  • Chapter
  • First Online:
Book cover Hyperthermic Oncology from Bench to Bedside

Abstract

In liver cancer, there are two kinds of liver cancer. One is a primary hepatocellular carcinoma and the other is metastatic liver cancer.

As for the out-of case of a surgery indication of these cancers, administrations into the hepatic artery of an anticancer agent, an arterial-embolism treatment (TACE), RFA, transient embolization by Degradable Starch Microspheres with anticancer agent or systemic chemotherapy are performed.

At present, liver resection and transplantation can improve the survival rate of HCC, but long waiting time due to the shortage of donor organs may result in tumor progression. Given these limitations, many nonsurgical methods have been proposed. However, in each monotherapy of these, the curative effect is restrictive and a multidisciplinary treatment is needed.

In these cases, the combined effect of hyperthermia is very high.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–50. doi:10.1056/NEJM199903113401001.

    Article  CAS  PubMed  Google Scholar 

  2. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5–16. doi:10.1053/j.gastro.2004.09.011.

    Article  PubMed  Google Scholar 

  3. Nakayama H, Takayama T. Management before hepatectomy for hepatocellular carcinoma with cirrhosis. World J Hepatol. 2015;7(20):2292–302. doi:10.4254/wjh.v7.i20.2292.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M, Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF, Carrillo-Pérez DL. Diagnosis and treatment of hepatocellular carcinoma: an update. World J Hepatol. 2015;7:362–76.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–55.

    Article  PubMed  Google Scholar 

  6. Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384:2053–63.

    Article  PubMed  Google Scholar 

  7. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385:1124–35.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Echeverría N, Moratorio G, Cristina J, Moreno P. Hepatitis C virus genetic variability and evolution. World J Hepatol. 2015;7:831–45.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M. HCC expert panel of Japan society of hepatology management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan society of hepatology (JSH) 2010 updated version. Dig Dis. 2011;29:339–64.

    Article  PubMed  Google Scholar 

  10. Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, Kokudo N, Tanaka M, Takayama T, Kudo M. Management of hepatocellular carcinoma: report of consensus meeting in the 45th annual meeting of the Japan society of hepatology (2009). Hepatol Res. 2010;40:667–85.

    Article  PubMed  Google Scholar 

  11. Kudo M. Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer. 2012;1:62–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol. 2013;30:3–11.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Masatoshi Kudo, Osamu Matsui, Namiki Izumi, Hiroko Iijima, Masumi Kadoya, Yasuharu Imai, Takuji Okusaka, Shiro Miyayama, Kaoru Tsuchiya, Kazuomi Ueshima, Atsushi Hiraoka, Masafumi Ikeda, Sadahisa Ogasawara, Tatsuya Yamashita, Tetsuya Minami, Koichiro Yamakado, and on behalf of the Liver Cancer Study Group of Japan. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer. 2014; 3(3–4): 458–468. doi:10.1159/000343875.

    Google Scholar 

  14. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Ernst O, Sergent G, Mizrahi D, Delemazure O, Paris JC, L’Herminé C. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. AJR Am J Roentgenol. 1999;172:59–64.

    Article  CAS  PubMed  Google Scholar 

  16. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, Lencioni R. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2011;37:212–20.

    Article  PubMed  Google Scholar 

  17. Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, Raoul JL, Sangro B. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32:348–59.

    CAS  PubMed  Google Scholar 

  18. Terzi E, Golfieri R, Piscaglia F, Galassi M, Dazzi A, Leoni S, Giampalma E, Renzulli M, Bolondi L. Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”. J Hepatol. 2012;57:1258–67.

    Article  CAS  PubMed  Google Scholar 

  19. Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, Ayuso C, Llovet JM, Real MI, Bruix J. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolization (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol. 2012;56(6):1330–5. doi:10.1016/j.jhep.2012.01.008. Epub 2012 Feb 5.

    Article  PubMed  Google Scholar 

  20. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–38.

    Article  CAS  PubMed  Google Scholar 

  21. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the study of the Liver. J Hepatol. 2001;35:421–30.

    Article  CAS  PubMed  Google Scholar 

  22. Nagata Y, Hiraoka M, Nishimura Y, Masunaga S, Mitumori M, Okuno Y, Fujishiro M, Kanamori S, Horii N, Akuta K, Sasai K, Abe M, Fukuda Y. Clinical results of radiofrequency hyperthermia for malignant liver tumors. Int J Radiat Oncol Biol Phys. 1997;38(2):359–65.

    Article  CAS  PubMed  Google Scholar 

  23. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. SHARP investigators study group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. doi:10.1056/NEJMoa0708857.

    Article  CAS  PubMed  Google Scholar 

  24. Mustafa Raoof MD, Corr SJ, Zhu C, Cisneros BT, Kaluarachchi WD, Phounsavath S, Wilson LJ, Curley SA. Gold nanoparticles and radiofrequency in experimental models for hepatocellular carcinoma. Nanomedicine. 2014;10(6):1121–30. doi:10.1016/j.nano.2014.03.004.

    PubMed  PubMed Central  Google Scholar 

  25. Gannon CJ, Cherukuri P, Yakobson BI, Cognet L, Kanzius JS, Kittrell C, et al. Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field. Cancer. 2007;110(12):2654–65.

    Article  CAS  PubMed  Google Scholar 

  26. Patra CR, Bhattacharya R, Wang EF, Katarya A, Lau JS, Dutta S, et al. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res. 2008;68(6):1970–8.

    Article  CAS  PubMed  Google Scholar 

  27. Buckley AF, Burgart LJ, Sahai V, Kakar S. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol. 2008;129(2):245–51.

    Article  PubMed  Google Scholar 

  28. Thakur S, Singla A, Chawla Y, Rajwanshi A, Kalra N, Arora SK. Expansion of peripheral and intratumoral regulatory T-cells in hepatocellular carcinoma: a case-control study. Indian J Pathol Microbiol. 2011;54:448–53.

    Article  PubMed  Google Scholar 

  29. Gomez-Santos L, Luka Z, Wagner C, Fernandez-Alvarez S, Lu SC, Mato JM, Martinez-Chantar ML, Beraza N. Inhibition of natural killer cells protects the liver against acute injury in the absence of glycine N-methyltransferase. Hepatology. 2012;56:747–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Mesiano G, Todorovic M, Gammaitoni L, Leuci V, Giraudo Diego L, Carnevale-Schianca F, Fagioli F, Piacibello W, Aglietta M, Sangiolo D. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther. 2012;12:673–84.

    Article  CAS  PubMed  Google Scholar 

  31. Kim HM, Kang JS, Lim J, Kim JY, Kim YJ, Lee SJ, Song S, Hong JT, Kim Y, Han SB. Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model. Arch Pharm Res. 2009;32:781–7.

    Article  CAS  PubMed  Google Scholar 

  32. Mohamed F, Stuart OA, Glehen O, Urano M, Sugarbaker PH. Docetaxel and hyperthermia: factors that modify thermal enhancement. J Surg Oncol. 2004;88:14–20.

    Article  CAS  PubMed  Google Scholar 

  33. Xiao-Pu Wang, Meng Xu, Hong-Fei Gao, Jian-Fu Zhao, and Ke-Cheng Xu. Intraperitoneal perfusion of cytokine-induced killer cells with local hyperthermia for advanced hepatocellular carcinoma. World J Gastroenterol. 2013 May 21; 19(19): 2956–2962. Published online 2013 May 21. doi:10.3748/wjg.v19.i19.2956.

    Google Scholar 

  34. Ito A, Okamoto N, Yamaguchi M, Kawabe Y, Kamihira M. Heat-inducible transgene expression with transcriptional amplification mediated by a transactivator. Int J Hyperthermia. 2012;28:788–98.

    Article  CAS  PubMed  Google Scholar 

  35. Köhne CH, Lenz HJ. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist. 2009;14:478–88.

    Article  PubMed  Google Scholar 

  36. Tabernero J, Van Cutsem E, Lakomý R, et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer. 2014;50:320–31.

    Article  CAS  PubMed  Google Scholar 

  37. Peeters M, Price TJ, Cervantes A, et al. Final results from a randomized phase 3 study of FOLFIRI {+/−} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol. 2014;25:107–16.

    Article  CAS  PubMed  Google Scholar 

  38. de Baere T, Elias D, Dromain C, et al. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol. 2000;175(6):1619–25.

    Article  PubMed  Google Scholar 

  39. Wasser K, Giebel F, Fischbach R, Tesch H, Landwehr P. Transarterial chemoembolization of liver metastases of colorectal carcinoma using degradable starch microspheres (Spherex): personal investigations and review of the literature. Radiologe. 2005;45(7):633–43.

    Article  CAS  PubMed  Google Scholar 

  40. Pernot S, Artru P, Mithieux F, Marsot J, Watkin E, Pellerin O, Lledo G, Chalabreysse P, Desramé J, Taieb J. Clin Res Hepatol Gastroenterol. Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial. 2015 Jun 30. pii: S2210-7401(15) 00134–5. doi:10.1016/j.clinre.2015.06.004.

    Google Scholar 

  41. Angele MK, Albertsmeier M, Prix NJ, Hohenberger P, Abdel-Rahman S, Dieterle N, Schmidt M, Mansmann U, Bruns CJ, Issels RD, Jauch KW, Lindner LH. Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: a subgroup analysis of a randomized phase-III multicenter study. Ann Surg. 2014;260(5):749–54. doi:10.1097/SLA.0000000000000978. discussion 754–6.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, Abdel-Rahman S, Daugaard S, Salat C, Wendtner CM, Vujaskovic Z, Wessalowski R, Jauch KW, Dürr HR, Ploner F, Baur-Melnyk A, Mansmann U, Hiddemann W, Blay JY, Hohenberger P; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-STBSG); European Society for Hyperthermic Oncology (ESHO). Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 2010 Jun;11(6):561–70. doi:10.1016/S1470-2045(10)70071-1. Epub 2010 Apr 29.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kokura Lab. Faculty of Health and Medical Sciences, Kyoto Gakuen University, 18, Gotanda-cho, Yamanouchi, Ukyo-ku, Kyoto-shi, Kyoto, 615-8577, Japan

    Satoshi Kokura

Authors
  1. Satoshi Kokura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satoshi Kokura .

Editor information

Editors and Affiliations

  1. Kokura Lab, Health and Medical Sciences, Kyoto Gakuen University, Kyoto, Kyoto, Japan

    Satoshi Kokura

  2. Department of Inflammation and Immunolog, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan

    Toshikazu Yoshikawa

  3. Department of Radiation Oncology, Nara Medical University, Kashihara, Nara, Japan

    Takeo Ohnishi

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media Singapore

About this chapter

Cite this chapter

Kokura, S. (2016). Combination with Hyperthermia and Chemotherapy: Liver Cancer. In: Kokura, S., Yoshikawa, T., Ohnishi, T. (eds) Hyperthermic Oncology from Bench to Bedside. Springer, Singapore. https://doi.org/10.1007/978-981-10-0719-4_25

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-0719-4_25

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-0717-0

  • Online ISBN: 978-981-10-0719-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation